2018-10-30 16:00Financial Performance - Operating revenue for the first nine months reached approximately RMB 6.92 billion, representing a year-on-year growth of 21.90%[11] - Net profit attributable to shareholders for the first nine months was approximately RMB 1.93 billion, an increase of 81.40% year-on-year[11] - Basic earnings per share rose by 71.68% to RMB 1.94 compared to the same period last year[11] - Total revenue for Q3 2018 reached ¥2,511,927,822.68, an increase of 24.7% compared to ¥2,012,503,890.39 in Q3 2017[35] - Year-to-date revenue for the first nine months of 2018 was ¥6,921,135,001.68, up 22.0% from ¥5,677,878,889.76 in the same period last year[35] - Net profit for Q3 2018 was ¥675,098,306.24, a significant increase of 102.2% compared to ¥333,219,404.86 in Q3 2017[37] - The total comprehensive income attributable to the parent company for the first nine months of 2018 reached ¥1,892,055,439.56, an increase from ¥1,085,103,690.61 in the previous year, reflecting a growth of about 74.5%[39] - The net profit attributable to the parent company for Q3 2018 was ¥656,479,057.10, compared to ¥320,595,274.83 in the same period last year, representing a growth of approximately 104.9%[38] Assets and Liabilities - Total assets increased by 36.33% to approximately RMB 17.15 billion compared to the end of the previous year[11] - The total amount of receivables increased by 32.72% to ¥1,873,291,487.26 from ¥1,411,480,641.19, driven by revenue growth in laboratory services and clinical business in China[21] - The company’s total liabilities increased significantly, with current liabilities rising by 1,443.77% to ¥262,084,495.26 from ¥16,976,863.67, due to the reclassification of long-term payables[21] - The total liabilities of the company as of September 30, 2018, were CNY 6.13 billion, compared to CNY 5.84 billion at the beginning of the year, indicating an increase of approximately 5%[30] - The total equity increased to ¥5,584,480,889.85 in Q3 2018, up 62.0% from ¥3,448,194,756.15 in Q3 2017[33] Cash Flow - The company’s cash and cash equivalents decreased by 62.22% to ¥933,948,063.25 from ¥2,472,390,524.24, mainly due to increased expenditures on engineering projects and long-term equity investments[21] - The net cash flow from operating activities decreased by 18.25% to ¥917,299,030.50 from ¥1,122,083,544.29, primarily due to increased cash payments for goods and services[23] - Cash inflow from operating activities for the first nine months of 2018 was ¥6,870,317,684.12, an increase from ¥5,949,867,293.48 year-over-year[47] - Cash outflow from investment activities totaled ¥4,773,770,866.67, compared to ¥2,645,535,656.87 in the same period last year, resulting in a net cash flow of -¥4,590,197,969.81[48] - The company reported a net cash increase of -¥1,542,504,471.20 for the first nine months of 2018, compared to -¥1,202,158,882.44 in the same period last year[48] Research and Development - Research and development expenses rose by 30.86% to ¥297,004,655.82, up from ¥226,966,631.10, mainly due to investments in the DNA-encoded compound library project and other efficiency-enhancing R&D activities[19] - Research and development expenses for Q3 2018 were ¥119,479,914.24, an increase of 7.7% from ¥111,504,156.87 in Q3 2017[36] Employee and Talent Management - The company employed a total of 17,461 staff, with 6,599 holding a master's degree or above[7] - The company plans to maintain high service standards and industry-leading expertise through talent retention strategies[9] - The company approved a stock incentive plan on August 6, 2018, aimed at motivating employees and aligning their interests with shareholders[26] Shareholder Information - The total number of shareholders reached 55,754, indicating a broad investor base[14] - The company’s public offering led to a 67.44% increase in capital reserves to ¥5,071,826,087.69 from ¥3,029,093,859.31[22] Regulatory and Market Activities - The company plans to issue overseas listed foreign shares (H shares) and apply for listing on the Hong Kong Stock Exchange, with the proposal approved by the board on July 1, 2018[25] - The company is in the process of obtaining necessary approvals from regulatory bodies for its H share listing, with applications submitted to the China Securities Regulatory Commission and the Hong Kong Stock Exchange[25]